Efficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients.

Simple item page
dc.contributor.authorTowanabut, Sen_US
dc.contributor.authorRungreangyingyod, Len_US
dc.contributor.authorSuthisisang, Cen_US
dc.date.accessioned2009-05-27T20:38:06Z
dc.date.available2009-05-27T20:38:06Z
dc.date.issued2001-04-20en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractThe study on the efficacy and safety of gabapentin as an add-on therapy trial was performed in 10 refractory partial seizure cases at Prasat Neurological Institute, Thailand from September 1996 to July 1998. This was an open-labeled titration dose of gabapentin starting at 600 mg/day add-on to the previously prescribed conventional antiepileptic drugs (AEDs). In cases that seizures could not be controlled, gabapentin dose was increased by 300 mg per day every two weeks until the total dose of 3,000 mg or until the side effects became intolerable. The result revealed that gabapentin reduced frequency, duration and severity of seizures and also improved the patients' activities of daily living (ADL) even at the minimum dose of 600 mg. The optimal dose of gabapentin was in the range of 600 to 1,200 mg per day. Seven patients were seizure free at the end of the study. There were some precipitating factors that interfered with the efficacy of gabapentin in some patients such as stress, menstruation, fever, and alcohol intake. Weight gain, somnolence, nystagmus, and dizziness were the major adverse events in these patients, whereas ataxia, tremor, and diplopia were found with gabapentin in a dose higher than 1,800 mg/day. These adverse events were mild and transient. No patients withdrew from the study due to adverse drug reactions. In addition, gabapentin did not alter conventional AED blood level and routine laboratory parameters. In conclusion, gabapentin was effective and well tolerated as an add-on therapy in refractory partial epileptic Thai patients.en_US
dc.description.affiliationDepartment of Medical Services, Prasat Neurological Institute, Bangkok, Thailand.en_US
dc.identifier.citationTowanabut S, Rungreangyingyod L, Suthisisang C. Efficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients. Journal of the Medical Association of Thailand. 2001 Apr; 84(4): 554-61en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/43356
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAcetic Acids --therapeutic useen_US
dc.subject.meshActivities of Daily Livingen_US
dc.subject.meshAdulten_US
dc.subject.meshAminesen_US
dc.subject.meshAnticonvulsants --therapeutic useen_US
dc.subject.meshCyclohexanecarboxylic Acidsen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEpilepsies, Partial --drug therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshgamma-Aminobutyric Aciden_US
dc.titleEfficacy and safety of gabapentin as an add-on therapy in refractory partial epileptic patients.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand